In this grant cycle, The Children's Hospital of Philadelphia (CHOP) will continue its previous 30 years of contributions to CCG. Specifically, CHOP will enter large numbers of patients on therapeutic trials, diligently supply patient samples for biologic and translational studies, carry out both institutional and CCG-linked pilot studies, and provide a vast and varied repetoire of young and mature talent and scientific leadership. In the past cycle, CHOP's Neuro-Oncology pilot studies were templates for 4 CCG Phase I and Phase II studies. In this cycle the Neuro-Oncology Program will introduce novel routes of delivery, targetted therapy, and exploration of neurofibromatosis type 1(NF-1) to probe the interface of genetics and brain tumors. In collaboration with the Neuro-Oncology Program, the Neuroblastoma Program will develop the TRK group of receptors for diagnosis prognosis and therapy. Based on CHOP pilot studies, the Leukemia Group will propose to CCG protracted, reduced-dose craniospinal irradiation of CNS relapse and established CNS disease and will introduce the repetitive reinduction/reconsolidation strategy for marrow relapse. CCG- supported CHOP laboratory investigation in leukemia includes genetic epidemiology of treatment-related leukemias and infant leukemia and the pediatric myelodysplastic and myeloproliferative syndromes. The CHOP Solid Tumor Group's pilot study of interval compression is being incorporated into the next phase III Ewing's trial. PCR analysis of t(2;13) and other fusion genes will be used for detection of minimal residual disease and for development of targetted therapy. The Division of Oncology's new Experimental Therapeutics Program will investigate unique biologics such as the HLA independent TALL-104 cell line, TRK targetted CEP-751, and IGFR soluble receptor and antisense the IGF1 receptor. CHOPs Transition Program aims to be a prototype for follow-up of survivors, promoting good preventive health strategies and good research. The first transition study seeks to define predisposing genetic risk factors in patients who have second malignant neoplasms. The interactions of CHOP and CCG are bidirectional and are mutually rewarding for both.

Agency
National Institute of Health (NIH)
Institute
National Cancer Institute (NCI)
Type
Cooperative Clinical Research--Cooperative Agreements (U10)
Project #
5U10CA011796-33
Application #
6475720
Study Section
Subcommittee G - Education (NCI)
Program Officer
Smith, Malcolm M
Project Start
1994-03-11
Project End
2002-11-30
Budget Start
2001-12-01
Budget End
2002-11-30
Support Year
33
Fiscal Year
2002
Total Cost
$405,880
Indirect Cost
Name
Children's Hospital of Philadelphia
Department
Type
DUNS #
073757627
City
Philadelphia
State
PA
Country
United States
Zip Code
19104
Kelly, Kimberly A; Bardeesy, Nabeel; Anbazhagan, Rajesh et al. (2008) Targeted nanoparticles for imaging incipient pancreatic ductal adenocarcinoma. PLoS Med 5:e85
Faca, Vitor M; Song, Kenneth S; Wang, Hong et al. (2008) A mouse to human search for plasma proteome changes associated with pancreatic tumor development. PLoS Med 5:e123
Kimmelman, Alec C; Hezel, Aram F; Aguirre, Andrew J et al. (2008) Genomic alterations link Rho family of GTPases to the highly invasive phenotype of pancreas cancer. Proc Natl Acad Sci U S A 105:19372-7
Neudorf, Steven; Sanders, Jean; Kobrinsky, Nathan et al. (2004) Allogeneic bone marrow transplantation for children with acute myelocytic leukemia in first remission demonstrates a role for graft versus leukemia in the maintenance of disease-free survival. Blood 103:3655-61
Seitzman, Robin L; Glover, Dorie A; Meadows, Anna T et al. (2004) Self-concept in adult survivors of childhood acute lymphoblastic leukemia: a cooperative Children's Cancer Group and National Institutes of Health study. Pediatr Blood Cancer 42:230-40
Shamberger, Robert C; LaQuaglia, Michael P; Gebhardt, Mark C et al. (2003) Ewing sarcoma/primitive neuroectodermal tumor of the chest wall: impact of initial versus delayed resection on tumor margins, survival, and use of radiation therapy. Ann Surg 238:563-7; discussion 567-8
Casillas, Jacqueline N; Woods, William G; Hunger, Stephen P et al. (2003) Prognostic implications of t(10;11) translocations in childhood acute myelogenous leukemia: a report from the Children's Cancer Group. J Pediatr Hematol Oncol 25:594-600
Lange, Beverly J; Bostrom, Bruce C; Cherlow, Joel M et al. (2002) Double-delayed intensification improves event-free survival for children with intermediate-risk acute lymphoblastic leukemia: a report from the Children's Cancer Group. Blood 99:825-33
Ou, Shu Xiao; Han, Dehui; Severson, Richard K et al. (2002) Birth characteristics, maternal reproductive history, hormone use during pregnancy, and risk of childhood acute lymphocytic leukemia by immunophenotype (United States). Cancer Causes Control 13:15-25
Cairo, M S; Krailo, M D; Morse, M et al. (2002) Long-term follow-up of short intensive multiagent chemotherapy without high-dose methotrexate ('Orange') in children with advanced non-lymphoblastic non-Hodgkin's lymphoma: a children's cancer group report. Leukemia 16:594-600

Showing the most recent 10 out of 21 publications